Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06246630

In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Led by Ruijin Hospital · Updated on 2024-05-16

20

Participants Needed

1

Research Sites

116 weeks

Total Duration

On this page

Sponsors

R

Ruijin Hospital

Lead Sponsor

C

Chongqing Kingbiotech Co.,Ltd

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic Pancreatic neuroendocrine tumors. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response

CONDITIONS

Official Title

In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years old
  • Histologically or cytologically confirmed locally advanced or metastatic pancreatic neuroendocrine tumor
  • Surgery is impossible or not aimed at radical cure
  • Able to provide fresh tumor tissue specimens for organoid culture
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • Expected survival time of at least six months
  • Informed consent given and able to comply with follow-up requirements
Not Eligible

You will not qualify if you...

  • Other malignancies within the past 5 years, except cured basal cell carcinoma of the skin
  • Severe cardiovascular events or myocardial infarction within 12 months before the study
  • Psychiatric disorders or substance abuse with inability to abstain
  • Pregnant or breastfeeding women
  • Other serious systemic diseases or conditions that make participation unsuitable according to the researcher

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China, 200025

Actively Recruiting

Loading map...

Research Team

J

Jiabin JIN, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here